Cas:33056-03-0 (Methylcyclopentadienyl)molybdenum tricarbonyl manufacturer & supplier

Chemical Name:(Methylcyclopentadienyl)molybdenum tricarbonyl

CAS.NO:33056-03-0

Synonyms:MFCD00151576;methylcyclopentadienylmolybdenum tricarbonyl dimer

Molecular Formula:C₁₈H₁₄Mo₂O₆

Molecular Weight:518.22000

HS Code:

Physical and Chemical Properties:

Melting point:150ºC (dec.)(lit.)

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:521.89000

LogP:1.57520

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00151576 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methylcyclopentadienylmolybdenum tricarbonyl dimer physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methylcyclopentadienylmolybdenum tricarbonyl dimer Use and application,methylcyclopentadienylmolybdenum tricarbonyl dimer technical grade,usp/ep/jp grade.

Related News: The CTSuccess service uses Catalent��s proprietary StartScoreTM evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics. (Methylcyclopentadienyl)molybdenum tricarbonyl manufacturer The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months. (Methylcyclopentadienyl)molybdenum tricarbonyl supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. (Methylcyclopentadienyl)molybdenum tricarbonyl vendor Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. (Methylcyclopentadienyl)molybdenum tricarbonyl factory Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.